Cargando…
Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
Targeted therapy with tyrosine kinase inhibitors has led to a substantial improvement in the standard of care for patients with advanced or metastatic clear cell renal cell carcinoma. Because the mechanism of action, metabolism and transport of tyrosine kinase inhibitors can affect outcome and toxic...
Autores principales: | Ganapathi, Ram N, Bukowski, Ronald M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334544/ https://www.ncbi.nlm.nih.gov/pubmed/22212486 http://dx.doi.org/10.1186/gm295 |
Ejemplares similares
-
The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012) -
Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012) -
Prognostic value of single‐nucleotide polymorphisms for extranodal natural killer/T‐cell lymphoma: the identification of risk factors in the molecular era
por: Yoon, Sang Eun, et al.
Publicado: (2021) -
Highlight—Stacking the Deck: Heritage and Environment Shape Nucleotide Composition in Prokaryotes
por: Venton, Danielle
Publicado: (2015) -
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)